WSJ
02 Jul 2026, 05:50 UTC · 2h ago
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
WSJ
02 Jul 2026, 05:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Search tags
What the story claims
1 claim · each scored for market impact
The experimental drug divarasib demonstrated meaningful improvements in overall survival and progression-free survival. — Positive clinical trial outcomes for survival metrics significantly increase the probability of FDA approval and future commercial success.
+0.80Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Continue reading
6 related stories
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
5h ago
